

ChroMedX Finalizes Cartridge For HemoPalm Prototype

April 10, 2017 – ChroMedX Corp. (the “**Company**”) (CSE: CHX, OTC: MNLIF, Frankfurt: E1Y2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the completion of the HemoPalm cartridge design for integration and use with the upcoming HemoPalm analyzer prototype.

The HemoPalm Cartridge is the most integral part of the technology and is protected globally by issued and pending international patents. The development of the cartridge commenced in July 2014 with the formation of the Company and has been an ongoing collaboration with Hochuen International Corp. of Shenzhen, China since December 2015.

“The cartridge design has been the most challenging step of the prototype development and one of the more critical parts as some of the other analyzer components rely on the completion of this design. The HemoPalm cartridge has evolved through many revisions and functional testing and I am very proud to report on the completion of the cartridge design as a significant milestone for the Company. This development allows us to move forward with methods of mass production and complete the cartridge intake which will finalize the assembly of the HemoPalm prototype.” said Ash Kaushal, President & CEO, ChroMedX Corp.

With the completion of the cartridge design the Company is now concentrated on evaluating the manufacturability and reproducibility of large quantities of the cartridge at a competitive cost, using injection molding instead of machining. The molded cartridges will be used for ongoing testing, calibration and validation of the HemoPalm analyzer prototype, which is near completion.

The ChroMedx development team is now working to finalize the cartridge intake mechanism for integration with the HemoPalm analyzer prototype which will be followed by the packaging of the completed prototype device.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

The HemoPalm Handheld Blood Analyzer System is the only handheld blood analysis technology which combines Blood Gases & Electrolytes with full CO-oximetry. Currently this combination is not available on any of the handheld analyzers on the market. Existing technologies require users to purchase a second device to carry out the CO-oximetry. The

CHROMEDX CORP

Suite 520 - 65 Queen Street West
Toronto, Ontario
M5H 2M5

Office: 647-872-9982
Toll-free/fax: 1-844-247-6633
Email: info@chromedx.com



CSE:CHX – OTC: MNLIF

Company's technology has the advantage of being able to offer a single handheld blood analyzer that provides all the required tests for Blood Gases & Electrolytes, with full CO-oximetry and bilirubin. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pin-prick site into the cartridge, providing an alternative to arterial blood. Drawing arterial blood is painful and can cause nerve damage. CO-oximetry is the measurement of five different hemoglobin species in blood.

The global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion \$US in 2015 and is projected to reach over 1.8 Billion by 2020.

Website: www.chromedx.com

Contact:

Investor Relations
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@chromedx.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com